PRMT7-IN-2
PRMT7-IN-2 (A33) is a selective PRMT7 inhibitor with an IC50 of 0.50 μM. PRMT7-IN-2 arrests cell cycle at G0/G1 phase, induces cell apoptosis, and inhibits cell growth in vivo and in vitro. PRMT7-IN-2 decreases the monomethylarginine level of PRMT7, increases expression of epithelial marker (E-cadherin, and reduces expression of mesenchymal markers such as N-cadherin, Vimentin, and ZEB2[1].
Product Specifications
CAS Number
3058094-83-7
UNSPSC
12352005
Target
Apoptosis; Histone Methyltransferase
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
98.26
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
COC1=CC(C2=NC3=C(C(NC4=CC=C(C5=C4)N=C(C=C5N)C)=N2)SC=C3)=CC(OC)=C1OC
Molecular Formula
C25H23N5O3S
Molecular Weight
473.55
References & Citations
[1]Li J, et al. Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer. J Med Chem. 2025 Apr 24;68 (8) :8244-8268.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Exodus 2 (CCL21) (NM_002989) Human Recombinant Protein
Cytochrome C (Mitochondrial Marker) (rCYCS/1010), CF740 conjugate, 0.1mg/mL
